Generic placeholder image

Recent Patents on Biotechnology

Editor-in-Chief

ISSN (Print): 1872-2083
ISSN (Online): 2212-4012

Research Article

Botanical Extracts and Compounds of Castanea Plants and Methods of Use: US20190125818A1 - The United States Patent Evaluation

Author(s): Tatiane Batista dos Santos, Denilson dos Santos Gomes, Agenor Gomes dos Santos Neto, Lívia Maria do Amorim Costa Gaspar and Daniela Droppa-Almeida*

Volume 18, Issue 2, 2024

Published on: 16 May, 2023

Page: [152 - 161] Pages: 10

DOI: 10.2174/1872208317666230420105000

Price: $65

Abstract

Background: Bacterial infections are increasingly difficult to combat, which makes them a threat to public health on a global level. Staphylococcus aureus is considered one of the main causes of infections in hospitals, as it has a variety of virulence factors, as well as is able to produce bacterial biofilms, which, consequently, bring numerous damages to public health as a result of increased resistance to conventional antibiotics and a longer hospital stay. Therefore, the use of compounds extracted from medicinal plants is a potential pharmaceutically acceptable target, as they do not have toxicity and the potential to disrupt biofilms produced by Staphylococcus aureus already evidenced, thus revealing their relevance to our study.

Objective: The objective of this work was to perform a critical analysis of a patent with natural extracts against bacterial biofilms found in the United States Patent and Trademark Office (USPTO) database, to map the possible bioactive compounds that may serve as potential future antimicrobial drugs.

Methods: A technological survey was carried out to verify existing patents using natural extracts with anti-biofilm potential. For this, it was searched with the keywords: Botanical extracts AND biofilms; which were performed in the United States Patent and Trademark Office (USPTO) database. Thus, the selected patent used a non-aqueous extract partitioned and vacuum-contracted, subsequently lyophilized for assays with antimicrobial potential. Because of this, a patent was analyzed regarding its chemistry, and biological activity, followed by a critical analysis of the technology proposed in the invention.

Results: When using the keywords Botanical extracts AND biofilms in the USPTO, it was possible to find twenty-two inventions; however, only four patents in the USPTO were in agreement with the proposal of the natural extract having antimicrobial activity and an anti-biofilm potential, of which two belonged to the same applicant with similar proposals. The key point of this invention was to enable the compounds of the Castanea sativa plant and its methods of obtaining the extract to present a significant antimicrobial action associated or not with antibiotics, promoting the development of new therapies against bacterial infections capable of disrupting biofilms. The invention developed a methodology for extracting Castanea sativa, in which pentacyclic triterpene compounds were found mostly in its leaves. Whereas for the extraction, the crude methanol extracts called extracts 224 from the ground leaves were made by maceration, filtered, combined, concentrated under pressure in rotary evaporators, and lyophilized. After that, they were resuspended in water and partitioned in succession with hexane, ethyl acetate, and butanol. The most active refined partition was the 224C extract with the solvent ethyl acetate, which was subjected to further fractionation using silica column chromatography. Resulting in the most refined extract, which was 224C-F2, capable of acting directly on the quorum sensing of bacteria, mainly Staphylococcus aureus, blocking the translation of RNAIII, including a series of exotoxins. Regarding the antimicrobial capacity against Staphylococcus aureus, it presented Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) of 1.56 μg/mL-1 and > 100 μg/mL -1, respectively.

Conclusion: Given the analyzed patent, it was possible to verify the importance of alternatives to reduce the impact of bacterial biofilms, which causes damage to industries in general and to health. From this, the invention analyzed has a promising proposal with antimicrobial potential focusing on the great impact of bacterial biofilms. Therefore, natural extracts with antibiofilmic potential can help to minimize the economic losses caused to health due to these multidrug-resistant microorganisms with different virulence mechanisms.

Keywords: Castanea sativa, bacterial biofilms, bacterial infections, multidrug resistant bacteria, USPTO, Staphylococcus aureus.

Graphical Abstract
[1]
Khan A, Miller WR, Arias CA. Mechanisms of antimicrobial resistance among hospital-associated pathogens. Expert Rev Anti Infect Ther 2018; 16(4): 269-87.
[http://dx.doi.org/10.1080/14787210.2018.1456919] [PMID: 29617188]
[2]
Giono-Cerezo S, Santos-Preciado JI, Morfín-Otero MR, Torres-López FJ, Alcántar-Curiel MD. Antimicrobial resistance. Its importance and efforts to control it. Gac Med Mex 2020; 156(2): 171-8.
[http://dx.doi.org/10.24875/GMM.M20000358] [PMID: 32285851]
[3]
Silva AS, Silva AL, Ribeiro AC, et al. Quorum sensing and its implications for bacterial biofilm formation in hospitals. J Infect Control 2020; 9(1): 473-84.
[http://dx.doi.org/10.37885/200901375]
[4]
Meade E, Slattery MA, Garvey M. Bacteriocins, potent antimicrobial peptides and the fight against multi drug resistant species: Resistance is futile? Antibiotics 2020; 9(1): 32.
[http://dx.doi.org/10.3390/antibiotics9010032] [PMID: 31963311]
[5]
Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr 2016; 4(2): 4.2.15.
[http://dx.doi.org/10.1128/microbiolspec.VMBF-0016-2015] [PMID: 27227291]
[6]
Barrasa-Villar JI, Aibar-Remón C, Prieto-Andrés P, Mareca-Doñate R, Moliner-Lahoz J. Impact on morbidity, mortality, and length of stay of hospital-acquired infections by resistant microorganisms. Clin Infect Dis 2017; 65(4): 644-52.
[http://dx.doi.org/10.1093/cid/cix411] [PMID: 28472416]
[7]
Quave CL, Lyles JT, Kavanaugh JS, et al. Castanea sativa (European Chestnut) leaf extracts rich in ursene and oleanene derivatives block Staphylococcus aureus virulence and pathogenesis without detectable resistance. PLoS One 2015; 10(8): e0136486.
[http://dx.doi.org/10.1371/journal.pone.0136486] [PMID: 26295163]
[8]
Falzon CC, Balabanova A. Phytotherapy. Prim Care 2017; 44(2): 217-27.
[http://dx.doi.org/10.1016/j.pop.2017.02.001] [PMID: 28501226]
[9]
Pandey PK. Castanea Sativa Mill-A review on its phytochemical and pharmacological profile. Pharma Innov 2018; 7(5): 94.
[10]
Lee AS, de Lencastre H, Garau J, et al. Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers 2018; 4(1): 18033.
[http://dx.doi.org/10.1038/nrdp.2018.33] [PMID: 29849094]
[11]
Fernando SA, Gray TJ, Gottlieb T. Healthcare-acquired infections: Prevention strategies. Intern Med J 2017; 47(12): 1341-51.
[http://dx.doi.org/10.1111/imj.13642] [PMID: 29224205]
[12]
Rodrigues R, Fonseca RP, Gomes O, Castro R. Risk factors, length of stay and in-hospital mortality of methicillin-resistant Staphylococcus aureus infections: A case-control study. Acta Med Port 2020; 33(3): 174-82.
[http://dx.doi.org/10.20344/amp.10952] [PMID: 32130096]
[13]
Mesrati I, Saidani M, Jemili M, Ferjeni S, Slim A, Boubaker IBB. Virulence determinants, biofilm production and antimicrobial susceptibility in Staphylococcus aureus causing device-associated infections in a Tunisian hospital. Int J Antimicrob Agents 2018; 52(6): 922-9.
[http://dx.doi.org/10.1016/j.ijantimicag.2018.05.004] [PMID: 29775684]
[14]
Quave CL, Lyles JT, Horswill AR. Research Foundation of the University of Iowa UIRF Emory University Patent US10195241B2, 2019.
[15]
Silva FCO, Ferreira MKA, Da Silva AW, Matos MGC, Magalhães FE, Da Silva PT. Bioactivities of Triterpenes isolated from plants: A brief review. Virtual J Chem 2020; 12(1): 1-14.
[16]
Choi HS, Han JY, Choi YE. Identification of triterpenes and functional characterization of oxidosqualene cyclases involved in triterpene biosynthesis in lettuce (Lactuca sativa). Plant Sci 2020; 301: 110656.
[http://dx.doi.org/10.1016/j.plantsci.2020.110656] [PMID: 33218626]
[17]
Silva FC, Duarte LP, Vieira FSA. Celastraceae: Sources of pentacyclic triterpenes with potential biological activity. Revista Virtual de Química 2014; 6(5): 1205-20.
[18]
Gossan DPA, Alabdul Magid A, Yao-Kouassi PA, et al. Antibacterial and cytotoxic triterpenoids from the roots of Combretum racemosum. Fitoterapia 2016; 110: 89-95.
[http://dx.doi.org/10.1016/j.fitote.2016.03.002] [PMID: 26946378]
[19]
Chrobak E, Bębenek E, Marciniec K, et al. New 30-substituted derivatives of pentacyclic triterpenes: preparation, biological activity, and molecular docking study. J Mol Struct 2021; 1226: 129394.
[http://dx.doi.org/10.1016/j.molstruc.2020.129394]
[20]
Nie A, Chao Y, Zhang X, Jia W, Zhou Z, Zhu C. Phytochemistry and pharmacological activities of Wolfiporia cocos (FA Wolf) Ryvarden & Gilb. Front Pharmacol 2020; 11: 505249.
[http://dx.doi.org/10.3389/fphar.2020.505249] [PMID: 33071776]
[21]
Fang Z, Li J, Yang R, Fang L, Zhang Y. A Review: The triterpenoid saponins and biological activities of Lonicera Linn. Molecules 2020; 25(17): 3773.
[http://dx.doi.org/10.3390/molecules25173773] [PMID: 32825106]
[22]
Shoham M, Greenberg M. Preventing the spread of infectious diseases: Antivirulents versus antibiotics. Future Microbiol 2017; 12(5): 365-8.
[http://dx.doi.org/10.2217/fmb-2017-0011] [PMID: 28339290]

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy